Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from D.Western Therapeutics Institute, Inc. ( (JP:4576) ) is now available.
D.Western Therapeutics Institute, Inc. reported its consolidated financial results for the fiscal year ended December 31, 2024. The company experienced a significant increase in net sales by 10.1% year-on-year, reaching 471 million yen. However, it also reported considerable losses in operating and ordinary profits, with a net loss attributable to owners of the parent amounting to 1,290 million yen. The financial position showed a decrease in total assets, net assets, and equity ratio compared to the previous year, indicating potential challenges in the company’s financial health. Stakeholders should be aware of the declined projections for the fiscal year ending December 31, 2025, with expected decreases in net sales and continued losses in profits.
More about D.Western Therapeutics Institute, Inc.
D.Western Therapeutics Institute, Inc. operates within the pharmaceutical industry and is listed on the Tokyo Stock Exchange. The company focuses on the development and commercialization of therapeutic products.
YTD Price Performance: -30.80%
Average Trading Volume: 3,351
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €40.19M
For an in-depth examination of 4576 stock, go to TipRanks’ Stock Analysis page.